Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment Failed
July 25 2014 - 5:03AM
Dow Jones News
By Nikki Houston
Bayer AG and Onyx Pharmaceuticals Inc. said Friday a Phase III
trial of Nexavar and capecitabine to treat advanced breast cancer
failed to meet its primary endpoint.
"We are disappointed that the trial did not show an improvement
in progression-free survival in patients with advanced breast
cancer," said Joerg Moeller, Bayer HealthCare's Head of Global
Development.
The result won't affect the drug's approved treatments for other
diseases, he added.
Nexavar, also known as sorafenib, is an oral drug developed and
marketed by Bayer HealthCare and Onyx Pharmaceuticals. Onyx
Pharmaceuticals is a subsidiary of Amgen Inc.
Write to Nikki Houston at nikki.houston@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Oct 2023 to Oct 2024